Antibodies for
Immunohistochemistry
IgG4 (MRQ-44)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
44315 IgG4 RTU M (MRQ-44)
7 ml Ready To Use
44652 IgG4 0,1 M (MRQ-44)
100 µl liquid Concentrated
44653 IgG4 1 M (MRQ-44)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Tonsil
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
Product Description
IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing
fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. As these patients tend to respond
favorably to steroid treatment, it is important to recognize this entity and differentiate it from such mimics as lymphoma. Clinical manifestations
are apparent in the pancreas, bile duct, gall bladder, lacrimal gland, salivary gland, retroperitoneum, kidney, lung, breast, thyroid, and prostate.
Immunohistochemical analyses in the case of IgG4-related sclerosing disease not only exhibits significantly more IgG4-positive plasma cells in
affected tissues, but also significantly higher IgG4/IgG ratios (typically > 30%).
Reference
1. Noriyuki Sakata, et al. Am J SurgPathol. April 2008; 32(4):553-559.
2. Sudhir Dhobale. et al. J ClinRheumatol. 2009; 15:354-357.
3. Yaqiong Li, et al. Pathology International. 2009; 59:636-641.
4. Wah Cheul, et al. Am J SurgPathol. 2009; 33:1058-1064.
5. Vikram Deshpande, et al. Modern Pathology. 2009; 22:1287-1295.
6. Yasuharu Sato, et al. Modern Pathology. 2009; 22:589-599.
7. Terumi Kamisawa, et al. Published online: May 21, 2009.
148
